PCRX in the 13F filings
Pacira Biosciences Inc · CUSIP 695127100
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 15 Aug 2025
- latest of these filings; the earliest 13 Aug 2025
- Managers listing it
- 5
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 4 listed it in both
- Shares listed
- 4,883,461
- combined, among listed positions
- Reported value
- $117m
- combined, at the quarter end
Among the 95 comparable managers: 3 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing PCRX in Q2 2025
5 of 5 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | 2,395,601 | $57m | 0.08% | Added | +155,000 | 13 Aug 2025 (the filing on sec.gov) |
| Balyasny Asset Management LLC | 2,130,733 | $51m | 0.08% | Added | +565,288 | 14 Aug 2025 (the filing on sec.gov) |
| PDT Partners LLC | 206,952 | $4.9m | 0.28% | Trimmed | -40 | 14 Aug 2025 (the filing on sec.gov) |
| Winton Group Ltd | 102,668 | $2.5m | 0.13% | New | new | 14 Aug 2025 (the filing on sec.gov) |
| Caxton Associates LLP | 47,507 | $1.1m | under 0.1% | Trimmed | -4,257 | 15 Aug 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Balyasny Asset Management LLCexisting position · 2,130,733 shares now+565,288
- Renaissance Technologies LLCexisting position · 2,395,601 shares now+155,000
- Winton Group Ltdnew position · 102,668 shares now+102,668
Reductions
- Caxton Associates LLPexisting position · 47,507 shares now-4,257
- PDT Partners LLCexisting position · 206,952 shares now-40
New positions and exits
New (1)
- Winton Group Ltd$2.5m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 3 | $232m | n.a. | n.a. |
| Q3 2013 | 3 | $325m | n.a. | n.a. |
| Q4 2013 | 2 | $349m | n.a. | n.a. |
| Q1 2014 | 3 | $399m | n.a. | n.a. |
| Q2 2014 | 3 | $525m | n.a. | n.a. |
| Q3 2014 | 8 | $891m | n.a. | n.a. |
| Q4 2014 | 6 | $510m | n.a. | n.a. |
| Q1 2015 | 3 | $396m | n.a. | n.a. |
| Q2 2015 | 4 | $357m | n.a. | n.a. |
| Q3 2015 | 7 | $180m | n.a. | n.a. |
| Q4 2015 | 5 | $659m | n.a. | n.a. |
| Q1 2016 | 5 | $344m | n.a. | n.a. |
| Q2 2016 | 6 | $194m | n.a. | n.a. |
| Q3 2016 | 4 | $62m | n.a. | n.a. |
| Q4 2016 | 2 | $41m | n.a. | n.a. |
| Q1 2017 | 3 | $33m | n.a. | n.a. |
| Q2 2017 | 5 | $71m | n.a. | n.a. |
| Q3 2017 | 2 | $53m | n.a. | n.a. |
| Q4 2017 | 5 | $64m | n.a. | n.a. |
| Q1 2018 | 6 | $37m | n.a. | n.a. |
| Q2 2018 | 3 | $23m | n.a. | n.a. |
| Q3 2018 | 7 | $133m | n.a. | n.a. |
| Q4 2018 | 9 | $143m | n.a. | n.a. |
| Q1 2019 | 8 | $152m | n.a. | n.a. |
| Q2 2019 | 9 | $234m | n.a. | n.a. |
| Q3 2019 | 10 | $130m | n.a. | n.a. |
| Q4 2019 | 7 | $228m | n.a. | n.a. |
| Q1 2020 | 9 | $190m | n.a. | n.a. |
| Q2 2020 | 8 | $307m | n.a. | n.a. |
| Q3 2020 | 5 | $344m | n.a. | n.a. |
| Q4 2020 | 5 | $335m | n.a. | n.a. |
| Q1 2021 | 4 | $313m | n.a. | n.a. |
| Q2 2021 | 6 | $303m | n.a. | n.a. |
| Q3 2021 | 6 | $251m | n.a. | n.a. |
| Q4 2021 | 6 | $269m | n.a. | n.a. |
| Q1 2022 | 6 | $332m | n.a. | n.a. |
| Q2 2022 | 5 | $239m | n.a. | n.a. |
| Q3 2022 | 5 | $206m | n.a. | n.a. |
| Q4 2022 | 5 | $144m | n.a. | n.a. |
| Q1 2023 | 6 | $174m | n.a. | n.a. |
| Q2 2023 | 8 | $174m | n.a. | n.a. |
| Q3 2023 | 5 | $111m | n.a. | n.a. |
| Q4 2023 | 5 | $102m | 3 | 2 |
| Q1 2024 | 3 | $108m | 2 | 2 |
| Q2 2024 | 4 | $113m | 3 | 1 |
| Q3 2024 | 4 | $41m | 3 | 2 |
| Q4 2024 | 4 | $68m | 3 | 2 |
| Q1 2025 | 7 | $178m | 6 | 1 |
| Q2 2025 | 5 | $117m | 3 | 2 |
| Q3 2025 | 4 | $109m | 0 | 4 |
| Q4 2025 | 5 | $57m | 17 | 11 |
| Q1 2026 | 3 | $45m | 6 | 20 |
| Q2 2026 | 3 | $49m | 14 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PCRX and LLY →PCRX and JNJ →PCRX and VRTX →Choose a stock to compare with PCRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PCRX, latest filings →Back to the 13F Explorer →